329 related articles for article (PubMed ID: 37119011)
1. VEXAS: is it time to reshape the nosology of clonal hematopoiesis?
Sujobert P; Largeaud L; Jamilloux Y; Heiblig M; Kosmider O
Expert Rev Hematol; 2023; 16(7):495-499. PubMed ID: 37119011
[TBL] [Abstract][Full Text] [Related]
2. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
[TBL] [Abstract][Full Text] [Related]
3. Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy.
Kanagal-Shamanna R; Beck DB; Calvo KR
Annu Rev Pathol; 2024 Jan; 19():479-506. PubMed ID: 37832948
[TBL] [Abstract][Full Text] [Related]
4. Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?
Kusne Y; Fernandez J; Patnaik MM
Semin Hematol; 2021 Oct; 58(4):226-229. PubMed ID: 34802544
[TBL] [Abstract][Full Text] [Related]
5. Clonal hematopoiesis in VEXAS syndrome.
Blood; 2023 Jul; 142(3):306. PubMed ID: 37471106
[No Abstract] [Full Text] [Related]
6. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
Osman A; Patel JL
Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
[TBL] [Abstract][Full Text] [Related]
7. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
[TBL] [Abstract][Full Text] [Related]
8. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms.
Xie Z; Chen EC; Mendez LM; Komrokji R; Zeidan AM
Cancer J; 2023 May-Jun 01; 29(3):130-137. PubMed ID: 37195768
[TBL] [Abstract][Full Text] [Related]
9. From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers.
Gurnari C; Visconte V
Leuk Res; 2023 Apr; 127():107038. PubMed ID: 36841022
[TBL] [Abstract][Full Text] [Related]
10. Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance).
Craven KE; Ewalt MD
Clin Lab Med; 2023 Dec; 43(4):565-576. PubMed ID: 37865503
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of clonal hematopoiesis in VEXAS syndrome.
Gutierrez-Rodrigues F; Kusne Y; Fernandez J; Lasho T; Shalhoub R; Ma X; Alessi H; Finke C; Koster MJ; Mangaonkar A; Warrington KJ; Begna K; Xie Z; Ombrello AK; Viswanatha D; Ferrada M; Wilson L; Go R; Kourelis T; Reichard K; Olteanu H; Darden I; Hironaka D; Alemu L; Kajigaya S; Rosenzweig S; Calado RT; Groarke EM; Kastner DL; Calvo KR; Wu CO; Grayson PC; Young NS; Beck DB; Patel BA; Patnaik MM
Blood; 2023 Jul; 142(3):244-259. PubMed ID: 37084382
[TBL] [Abstract][Full Text] [Related]
12. VEXAS syndrome with progression of MDS to MDS/MPN overlap syndrome.
Neupane K; Jayarangaiah A; Zhang Y; Kumar A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36549759
[TBL] [Abstract][Full Text] [Related]
13. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
Caponetti GC; Bagg A
Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
[TBL] [Abstract][Full Text] [Related]
14. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.
Gondek LP; DeZern AE
Lancet Haematol; 2020 Jan; 7(1):e73-e81. PubMed ID: 31810765
[TBL] [Abstract][Full Text] [Related]
15. VEXAS Syndrome: A Novelty in MDS Landscape.
Templé M; Kosmider O
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
[TBL] [Abstract][Full Text] [Related]
16. Utility of plasma cell-free DNA for
Gutierrez-Rodrigues F; Beerman I; Groarke EM; Patel BA; Spitofsky N; Dillon LW; Raffo DQ; Hourigan CS; Kajigaya S; Ferrucci L; Young NS
Haematologica; 2022 Aug; 107(8):1815-1826. PubMed ID: 34587721
[TBL] [Abstract][Full Text] [Related]
17. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome.
Lacombe V; Beucher A; Urbanski G; Le Corre Y; Cottin L; Croué A; Bouvier A
Exp Hematol Oncol; 2022 Feb; 11(1):6. PubMed ID: 35172893
[TBL] [Abstract][Full Text] [Related]
18. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
Tang G; Medeiros LJ; Wang SA
Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
[TBL] [Abstract][Full Text] [Related]
19. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
[TBL] [Abstract][Full Text] [Related]
20. VEXAS syndrome: A dermatological perspective.
Nguyen JK; Routledge D; van Der Weyden C; Blombery P; Angel CM; Johnson D; Goh MS; Lee A
Australas J Dermatol; 2022 Nov; 63(4):488-492. PubMed ID: 36197697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
